Advances in research on neuromodulation of ovarian cancer

LI Fan-Shu; SUN Yan-Rong; ZHANG Yan; LUAN Li-Ju; ZHANG Wei-Guang

doi:10.16098/j.issn.0529-1356.2024.05.018

PDF(1344 KB)

Acta Anatomica Sinica ›› 2024, Vol. 55 ›› Issue (5) : 647-653. DOI: 10.16098/j.issn.0529-1356.2024.05.018

Review

Advances in research on neuromodulation of ovarian cancer

LI Fan-shu¹ SUN Yan-rong² ZHANG Yan² LUAN Li-ju^2* ZHANG Wei-guang^2*

Author information +

History +

Abstract

Ovarian cancer is one of the most common gynecologic cancers in the world. Over the past few decades, there has been considerable research reporting on the mechanisms of cancer development and progression, with multiple nerve as well as neurotransmitters involved. Nerve innervation is also found in ovarian cancer. And in ovarian cancer, various nerves and neurotransmitters play different roles. They are involved in ovarian cancer cells’ proliferation metastasis, apoptosis and changes in the tumor microenvironment. Further understanding of the role of these nerve endings in the development of ovarian cancer is essential for understanding the mechanisms of cancer progression. This will be important for subsequent research focusing on tumor regulation. While glucocorticoids and sympathetic nerve-released norepinephrine are able to promote ovarian cancer progression, serotonin may inhibit cancer cell growth. Also, parasympathetic and sensory nerves are capable of having either a positive or negative effect on ovarian tumors. These relevant studies offer the possibility of new therapeutic options for oncology, it may be possible to mitigate the progression of cancer with inexpensive receptor inhibitors or agonists. This will facilitate the subsequent exploration of therapeutic possibilities forovarian cancer and other cancer-related treatments. In this review, we also present some insights into the role of the nervous system in the regulation of ovarian cancer, which we hope will provide new insights into the innervation and progression of ovarian cancer.

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Fan-shu SUN Yan-rong ZHANG Yan LUAN Li-ju ZHANG Wei-guang. Advances in research on neuromodulation of ovarian cancer[J]. Acta Anatomica Sinica. 2024, 55(5): 647-653 https://doi.org/10.16098/j.issn.0529-1356.2024.05.018

References

［1］ Faulkner S, Jobling P, March B, et al. Tumor neurobiology and the war of nerves in cancer ［J］. Cancer Discov, 2019, 9(6): 702-710.

［2］ Jin LY, Wang WW, Zhang H, et al. Effect of adverse psychological stress on the growth and epithelial growth factor receptor, phosphorylated protein kinase B and vascular endothelial growth factor expressions of human ovarian cancer cells transplanted into nude mice［J］. Acta Anatomica Sinica, 2018, 49(5): 617-623. (in Chinese)

金玲燕, 王弯弯, 张红, 等. 不良心理应激对人卵巢癌荷瘤裸鼠皮下移植瘤生长及表皮生长因子受体、磷酸化蛋白激酶B、血管内皮生长因子蛋白表达的影响［J］. 解剖学报, 2018, 49(5): 617-623.

［3］ Lutgendorf SK, Thaker PH, Arevalo JM, et al. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma ［J］. Cancer, 2018, 124(3): 580-586.

［4］ Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer ［J］. Clin Cancer Res, 2012, 18(5): 1201-1206.

［5］ Veneris JT, Huang L, Churpek JE, et al. Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer ［J］. Int J Gynecol Cancer, 2019, 29(2): 357-364.

［6］ Oppitz M, M?bus V, Brock S, et al. Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients ［J］. Gynecol Oncol, 2002, 85(1): 159-164.

［7］ Yan D, Liu X, Guo SW. Neuropeptides substance P and calcitonin gene related peptide accelerate the development and fibrogenesis of endometriosis ［J］. Sci Rep, 2019, 9(1): 2698.

［8］ Lutgendorf SK, Johnsen EL, Cooper B, et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma ［J］. Cancer, 2002, 95(4): 808-815.

［9］ Allen JK, Armaiz-Pena GN, Nagaraja AS, et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction ［J］. Cancer Res, 2018, 78(12): 3233-3242.

［10］ Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma ［J］. Nature medicine, 2006, 12(8): 939-944.

［11］ Choi M, Cho K, Lee S, et al. hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness ［J］. Oncogene, 2015, 34(26): 3402-3412.

［12］ Sanders BE, Yamamoto TM, Mcmellen A, et al. Targeting DUSP activity as a treatment for high grade serous ovarian carcinoma ［J］. Mol Cancer Ther, 2022, 21(8): 1285-1295.

［13］ Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis ［J］. J Clin Invest, 2010, 120(5): 1515-1523.

［14］ Bu S, Wang Q, Sun J, et al. Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis ［J］. Cell Death Dis, 2020, 11(8): 644.

［15］ Bayer JL, Spitz DR, Christensen D, et al. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma ［J］. Brain Behav Immun, 2015, 50: 58-62.

［16］ Lamboy-Caraballo R, Ortiz-Sanchez C, Acevedo-Santiago A, et al. Norepinephrine-induced DNA damage in ovarian cancer cells ［J］. Int J Mol Sci, 2020, 21(6): 2250.

［17］ Dash S, Yoder S, Mesa T, et al. Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells ［J］. Sci Rep, 2021, 11(1): 14334.

［18］ Nagaraja AS, Dorniak PL, Sadaoui NC, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis ［J］. Oncogene, 2016, 35(18): 2390-2397.

［19］ Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines ［J］. Clin Cancer Res, 2003, 9(12): 4514-4521.

［20］ Peters MAM, Meijer C, Fehrmann RSN, et al. Serotonin and dopamine receptor expression in solid tumours including rare cancers ［J］. Pathol Oncol Res, 2020, 26(3): 1539-1547.

［21］ Campos X, Mu?oz Y, Selman A, et al. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer ［J］. Gynecol Oncol, 2007, 104(1): 168-175.

［22］ Gautam J, Banskota S, Regmi SC, et al. Tryptophan hydroxylase 1 and 5-HT(7) receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling ［J］. Mol Cancer, 2016, 15(1): 75.

［23］ Henriksen R, Dizeyi N, Abrahamsson PA. Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumours ［J］. Anticancer Res, 2012, 32(4): 1361-1366.

［24］ Mrch LS, Dehlendorff C, Baandrup L, et al. Use of antidepressants and risk of epithelial ovarian cancer ［J］. Int J Cancer, 2017, 141(11): 2197-2203.

［25］ Qin X, Li J, Wang S, et al. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer ［J］. Theranostics, 2021, 11(14): 6950-6965.

［26］ Boyle SH, Brummett BH, Kuhn CM, et al. The effects of tryptophan enhancement and depletion on plasma catecholamine levels in healthy individuals ［J］. Psychosom Med, 2019, 81(1): 34-40.

［27］ Buonaiuto R, Neola G, Cecere SC, et al. Glucocorticoid receptor and ovarian cancer: from biology to therapeutic intervention ［J］. Biomolecules, 2023, 13(4): 653.

［28］ Yin L, Fang F, Song X, et al. The pro-adhesive and pro-survival effects of glucocorticoid in human ovarian cancer cells ［J］. J Mol Endocrinol, 2016, 57(1): 61-72.

［29］ Melhem A, Yamada SD, Fleming GF, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues ［J］. Clin Cancer Res, 2009, 15(9): 3196-3204.

［30］ Zhan X, Fletcher L, Dingle S, et al. Choline supplementation influences ovarian follicular development ［J］. Front Biosci (Landmark Ed), 2021, 26(12): 1525-1536.

［31］ Restaino AC, Walz A, Vermeer SJ, et al. Functional neuronal circuits promote disease progression in cancer ［J］. Sci Adv, 2023, 9(19): eade4443.

［32］ Harmych SJ, Kumar J, Bouni ME, et al. Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells ［J］. Exp Cell Res, 2020, 394(1): 112167.

［33］ Renz BW, Tanaka T, Sunagawa M, et al. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness ［J］. Cancer Disc, 2018, 8(11): 1458-1473.

［34］ Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression ［J］. Science, 2013, 341(6142): 1236361.

［35］ Barr JL, Kruse A, Restaino AC, et al. Intra-tumoral nerve-tracing in a novel syngeneic model of high-grade serous ovarian carcinoma ［J］. Cells, 2021, 10(12): 3491.

［36］ Tsukamoto H, Fujieda K, Miyashita A, et al. Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment ［J］. Cancer Res, 2018, 78(17): 5011-5022.

［37］ Fousek K, Horn LA, Palena C. Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression ［J］. Pharmacol Ther, 2021, 219: 107692.

［38］ Fonte RD, Strippoli S, Garofoli M, et al. Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids ［J］. Front Cell Dev Biol, 2023, 11: 1178316.

［39］ Ryu JW, Shin HY, Kim HS, et al. Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer ［J］. Front Oncol, 2023, 13: 1104521.